Long‐term safety of early discontinuation of antiseizure medication after resolution of acute provoked neonatal seizures
Epilepsia · 2026-06 · 67 (6) · 2836-2844
DOI: 10.1002/epi.70192 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Epilepsia, online erschienen am 13.03.2026. Verfasst von Hannah C Glass und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Weill Institute for Neuroscience, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Seizures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, Patient-Centered Outcomes Research Institute, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Objective
To assess long‐term safety of antiseizure medication (ASM) discontinuation after resolution of acute provoked neonatal seizures and prior to hospital discharge.
Methods
Prospective, observational, comparative effectiveness cohort study of neonates with acute provoked seizures born from July 2015 to March 2018, and followed until September 2024, at nine U.S. Neonatal Seizure Registry centers with Level IV neonatal intensive care units and Level IV pediatric epilepsy programs. Duration of ASM treatment was quantified as (1) discontinuation before discharge from the neonatal seizure admission or (2) maintenance at the time of hospital discharge. Outcomes were adjusted for propensity to receive ASM at discharge. Propensity for ASM maintenance was defined among enrolled participants by a logistic regression model including seizure etiology, gestational age, therapeutic hypothermia, worst electroencephalography (EEG) background, days of EEG seizures, and discharge neurological exam (all p ≤ .1 in a joint model, except etiology, which was included for face validity). The primary outcome was non‐inferiority of cognition (Wechsler Preschool and Primary Scale of Intelligence assessed at age 5–6 years). Secondary outcomes were non‐inferiority of functional development (Vineland Adaptive Behavior Scale, 3rd Edition, assessed at 3–8 years) and post‐neonatal epilepsy (assessed at 1–8 years).
Results
Among 284 children with at least one follow‐up, outcomes were similar in the discontinued vs maintained ASM groups for full‐scale IQ at age 5 years (adjusted difference +10 points), functional development at ages 3–8 years (adjusted difference 0 points), and post‐neonatal epilepsy at ages 1–8 years (adjusted hazard ratio .93, 95% confidence interval [CI] .48–1.80). Significance Prolonged administration of ASM for several months after resolution of acute provoked neonatal seizures may expose infants to unnecessary medications. These results provide additional evidence for safety of discontinuing ASM for most neonates soon after the resolution of acute provoked seizures—a practice that is recommended in the International League Against Epilepsy (ILAE) guideline for neonatal seizure management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Weill Institute for Neuroscience, University of California San Francisco, San Francisco, California, USA.
- Department of Pediatrics, UCSF Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.
- Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California, USA.
- Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Neurology, University of California Davis, Sacramento, California, USA.
- Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Hannah C Glass, Adam L Numis, Janet S Soul, Courtney J Wusthoff, Monica E Lemmon, Catherine J Chu, Shavonne L Massey, Cameron Thomas, Tayyba Anwar, Madison M Berl, Jennifer G Larson, Julie Sturza, Elizabeth E Rogers, Linda S Franck, Charles E McCulloch, Renée A Shellhaas
Förderung
- NINDS NIH HHS
- Patient-Centered Outcomes Research Institute
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Glass, H. C., Numis, A. L., Soul, J. S., Wusthoff, C. J., Lemmon, M. E., Chu, C. J., Massey, S. L., Thomas, C., Anwar, T., Berl, M. M., Larson, J. G., Sturza, J., Annis, D., Rogers, E. E., Franck, L. S., McCulloch, C. E., & Shellhaas, R. A. (2026). Long‐term safety of early discontinuation of antiseizure medication after resolution of acute provoked neonatal seizures. Epilepsia, 67(6), 2836-2844. https://doi.org/10.1002/epi.70192
Vancouver
Glass HC, Numis AL, Soul JS, Wusthoff CJ, Lemmon ME, Chu CJ, et al. Long‐term safety of early discontinuation of antiseizure medication after resolution of acute provoked neonatal seizures. Epilepsia. 2026;67(6):2836-2844. doi:10.1002/epi.70192
BibTeX
@article{Glass2026,
author = {Glass, Hannah C and Numis, Adam L and Soul, Janet S and Wusthoff, Courtney J and Lemmon, Monica E and Chu, Catherine J and Massey, Shavonne L and Thomas, Cameron and Anwar, Tayyba and Berl, Madison M and Larson, Jennifer G and Sturza, Julie and Annis, Dana and Rogers, Elizabeth E and Franck, Linda S and McCulloch, Charles E and Shellhaas, Renée A},
title = {Long‐term safety of early discontinuation of antiseizure medication after resolution of acute provoked neonatal seizures},
journal = {Epilepsia},
year = {2026},
volume = {67},
number = {6},
pages = {2836--2844},
doi = {10.1002/epi.70192}
}
EUVIMED